Abstract
Prostate cancer is the most common cancer among males. Advanced prostate cancer could develop into metastatic castration-resistant prostate cancer (mCRPC), which is a challenge in the diagnosis and treatment. The prognosis and quality of life of patients can be significantly improved by using radiolabeled prostate-specific membrane antigen (PSMA) ligands for localization and targeted therapy of mCRPC. This review summarizes the research progress of radiolabeled PSMA ligands in theranostics of mCRPC including SPECT imaging, PET imaging, and brachytherapy. Key words: Prostatic neoplasms, castration-resistant; Radioactive tracers; Prostate-specific membrane antigen; Trends
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
